Logo

'Are we seeing long-term shifts in the Scientific Research Landscape?'
Friday 2 October, 10:00 - 11:00 BST
Kindly hosted by Domainex

OBN Digital Event:
'Are we seeing long-term shifts in the Scientific Research Landscape' 

Kindly hosted by Domainex


This edition of OBN’s Digital Event series is kindly hosted by Domainex and will address how major global events such as the ongoing pandemic is impacting the research focus of R&D companies  - and whether these shifts are temporary or more long term. 

Will we see a change in direction in how drugs are developed and the support required by companies throughout each stage of development?


Keynote Speakers:

  1. Tom Mander, CEO of Domainex will share an update on how the function and role of organisations such as Domainex have evolved and where they are heading in the future.  What are the areas they are seeing a shift in and what are the factors determing these changes e.g. a focus on infectious diseases or government funding patterns.
     
  2. Ray Boffey, Head of Chemistry at Domainex will share his insight into the evolution of their chemistry pipeline and how taking an integrated approach to medicinal chemistry, biochemistry and computational chemistry can speed up project timelines for R&D companies; showing that effective integration includes bringing together scientific teams and embracing innovation.
     
  3. Helen Philippou, Founder Director of LUNAC Therapeutics, 'Drug Discovery: From Academia to Start-Up'.  An interesting and unique case study from an R&D company that Domainex have recently collaborated with.

About the event:

The audience willl have the opportunity to ask the speakers questions after the presentations.  

This session will be run in a live format, with registration open for both OBN Members and Non-Members.  A private partnering service will also be available for delegates to book meetings. 

OBN Members - Complimentary
Non-Members - £25+VAT

This digital event is kindly hosted by:




Domainex is Europe's fastest growing drug discovery CRO. It serves pharmaceutical, biotechnology, academic and patient foundations globally. Domainex’s drug discovery service business was established in 2001 and since that time has continued to expand to serve a wider range of international clients including UCB, FORMA Therapeutics, St George’s University, and The Institute of Cancer Research. Their expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year.

Processing. Please wait.
Loading...